ID   CHLE_HUMAN              Reviewed;         602 AA.
AC   P06276; A8K7P8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Cholinesterase;
DE            EC=3.1.1.8;
DE   AltName: Full=Acylcholine acylhydrolase;
DE   AltName: Full=Butyrylcholine esterase;
DE   AltName: Full=Choline esterase II;
DE   AltName: Full=Pseudocholinesterase;
DE   Flags: Precursor;
GN   Name=BCHE; Synonyms=CHE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetus;
RX   PubMed=3035536; DOI=10.1073/pnas.84.11.3555;
RA   Prody C.A., Zevin-Sonkin D., Gnatt A., Goldberg O., Soreq H.;
RT   "Isolation and characterization of full-length cDNA clones coding for
RT   cholinesterase from fetal human tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:3555-3559(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=3477799; DOI=10.1073/pnas.84.19.6682;
RA   McTiernan C., Adkins S., Chatonnet A., Vaughan T.A., Bartels C.F.,
RA   Kott M., Rosenberry T.L., la Du B.N., Lockridge O.;
RT   "Brain cDNA clone for human cholinesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6682-6686(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2322535; DOI=10.1021/bi00453a015;
RA   Arpagaus M., Kott M., Vatsis K.P., Bartels C.F., la Du B.N.,
RA   Lockridge O.;
RT   "Structure of the gene for human butyrylcholinesterase. Evidence for a
RT   single copy.";
RL   Biochemistry 29:124-131(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-567.
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 29-602, AND SIGNAL SEQUENCE CLEAVAGE SITE.
RC   TISSUE=Plasma;
RX   PubMed=3542989;
RA   Lockridge O., Bartels C.F., Vaughan T.A., Wong C.K., Norton S.E.,
RA   Johnson L.L.;
RT   "Complete amino acid sequence of human serum cholinesterase.";
RL   J. Biol. Chem. 262:549-557(1987).
RN   [7]
RP   PROTEIN SEQUENCE OF 29-37; 43-68; 71-163; 167-290; 294-522; 528-543
RP   AND 549-602, SIGNAL SEQUENCE CLEAVAGE SITE, GLYCOSYLATION, AND
RP   HOMOTETRAMERIZATION.
RC   TISSUE=Plasma;
RX   PubMed=20946535; DOI=10.1111/j.1423-0410.2010.01415.x;
RA   Weber A., Butterweck H., Mais-Paul U., Teschner W., Lei L.,
RA   Muchitsch E.M., Kolarich D., Altmann F., Ehrlich H.J., Schwarz H.P.;
RT   "Biochemical, molecular and preclinical characterization of a double-
RT   virus-reduced human butyrylcholinesterase preparation designed for
RT   clinical use.";
RL   Vox Sang. 100:285-297(2011).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   PubMed=3115973;
RA   Lockridge O., Adkins S., la Du B.N.;
RT   "Location of disulfide bonds within the sequence of human serum
RT   cholinesterase.";
RL   J. Biol. Chem. 262:12945-12952(1987).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-509 AND ASN-514.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-45; ASN-85; ASN-369;
RP   ASN-483; ASN-509 AND ASN-514.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   GLYCOSYLATION AT ASN-45; ASN-85; ASN-134; ASN-269; ASN-284; ASN-369
RP   AND ASN-483, AND CHARACTERIZATION OF GLYCOSYLATION.
RX   PubMed=18203274; DOI=10.1002/pmic.200700720;
RA   Kolarich D., Weber A., Pabst M., Stadlmann J., Teschner W.,
RA   Ehrlich H., Schwarz H.P., Altmann F.;
RT   "Glycoproteomic characterization of butyrylcholinesterase from human
RT   plasma.";
RL   Proteomics 8:254-263(2008).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND SUBUNIT.
RX   PubMed=19542320; DOI=10.1124/mol.109.055665;
RA   Chilukuri N., Duysen E.G., Parikh K., diTargiani R., Doctor B.P.,
RA   Lockridge O., Saxena A.;
RT   "Adenovirus-transduced human butyrylcholinesterase in mouse blood
RT   functions as a bioscavenger of chemical warfare nerve agents.";
RL   Mol. Pharmacol. 76:612-617(2009).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-134 AND ASN-284.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   GLYCOSYLATION AT ASN-284.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=19452557; DOI=10.1002/prot.22442;
RA   Amitay M., Shurki A.;
RT   "The structure of G117H mutant of butyrylcholinesterase: nerve agents
RT   scavenger.";
RL   Proteins 77:370-377(2009).
RN   [16]
RP   PHOSPHORYLATION AT SER-226.
RX   PubMed=22444575; DOI=10.1016/j.aca.2012.02.023;
RA   Aryal U.K., Lin C.T., Kim J.S., Heibeck T.H., Wang J., Qian W.J.,
RA   Lin Y.;
RT   "Identification of phosphorylated butyrylcholinesterase in human
RT   plasma using immunoaffinity purification and mass spectrometry.";
RL   Anal. Chim. Acta 723:68-75(2012).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANT BCHE DEFICIENCY ASP-232.
RX   PubMed=25054547; DOI=10.1371/journal.pone.0101552;
RA   Delacour H., Lushchekina S., Mabboux I., Bousquet A., Ceppa F.,
RA   Schopfer L.M., Lockridge O., Masson P.;
RT   "Characterization of a novel BCHE 'silent' allele: point mutation
RT   (p.Val204Asp) causes loss of activity and prolonged apnea with
RT   suxamethonium.";
RL   PLoS ONE 9:E101552-E101552(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   SUBSTRATE, SUBUNIT, GLYCOSYLATION AT ASN-85; ASN-134; ASN-269; ASN-369
RP   AND ASN-513, DISULFIDE BONDS, AND ACTIVE SITE.
RX   PubMed=12869558; DOI=10.1074/jbc.M210241200;
RA   Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., Nachon F.;
RT   "Crystal structure of human butyrylcholinesterase and of its complexes
RT   with substrate and products.";
RL   J. Biol. Chem. 278:41141-41147(2003).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   ECHOTHIOPHATE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-85; ASN-134;
RP   ASN-269; ASN-369 AND ASN-513.
RX   PubMed=15667209; DOI=10.1021/bi048238d;
RA   Nachon F., Asojo O.A., Borgstahl G.E.O., Masson P., Lockridge O.;
RT   "Role of water in aging of human butyrylcholinesterase inhibited by
RT   echothiophate: the crystal structure suggests two alternative
RT   mechanisms of aging.";
RL   Biochemistry 44:1154-1162(2005).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS), DISULFIDE BONDS, GLYCOSYLATION
RP   AT ASN-85; ASN-134; ASN-369 AND ASN-513, AND SUBUNIT.
RX   PubMed=17768338; DOI=10.1107/S1744309107037335;
RA   Ngamelue M.N., Homma K., Lockridge O., Asojo O.A.;
RT   "Crystallization and X-ray structure of full-length recombinant human
RT   butyrylcholinesterase.";
RL   Acta Crystallogr. F 63:723-727(2007).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   MERCURY IONS AND BUTANOIC ACID, DISULFIDE BONDS, GLYCOSYLATION AT
RP   ASN-85; ASN-134; ASN-269; ASN-369 AND ASN-513, AND ENZYME REGULATION.
RX   PubMed=17355286; DOI=10.1111/j.1742-4658.2007.05732.x;
RA   Frasco M.F., Colletier J.-P., Weik M., Carvalho F., Guilhermino L.,
RA   Stojan J., Fournier D.;
RT   "Mechanisms of cholinesterase inhibition by inorganic mercury.";
RL   FEBS J. 274:1849-1861(2007).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   TABUN, ENZYME REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   GLYCOSYLATION AT ASN-85; ASN-134; ASN-284; ASN-369 AND ASN-513.
RX   PubMed=18975951; DOI=10.1021/ja804941z;
RA   Carletti E., Li H., Li B., Ekstroem F., Nicolet Y., Loiodice M.,
RA   Gillon E., Froment M.T., Lockridge O., Schopfer L.M., Masson P.,
RA   Nachon F.;
RT   "Aging of cholinesterases phosphylated by tabun proceeds through O-
RT   dealkylation.";
RL   J. Am. Chem. Soc. 130:16011-16020(2008).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-557 IN COMPLEX WITH TABUN
RP   ANALOGS, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   GLYCOSYLATION AT ASN-85; ASN-134; ASN-269; ASN-284; ASN-369 AND
RP   ASN-513, AND ENZYME REGULATION.
RX   PubMed=19368529; DOI=10.1042/BJ20090091;
RA   Carletti E., Aurbek N., Gillon E., Loiodice M., Nicolet Y.,
RA   Fontecilla-Camps J.C., Masson P., Thiermann H., Nachon F., Worek F.;
RT   "Structure-activity analysis of aging and reactivation of human
RT   butyrylcholinesterase inhibited by analogues of tabun.";
RL   Biochem. J. 421:97-106(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 29-557 IN COMPLEX WITH
RP   TACRINE, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-85; ASN-134;
RP   ASN-269; ASN-284; ASN-369 AND ASN-513.
RX   PubMed=23679855; DOI=10.1042/BJ20130013;
RA   Nachon F., Carletti E., Ronco C., Trovaslet M., Nicolet Y., Jean L.,
RA   Renard P.Y.;
RT   "Crystal structures of human cholinesterases in complex with huprine W
RT   and tacrine: elements of specificity for anti-Alzheimer's drugs
RT   targeting acetyl- and butyryl-cholinesterase.";
RL   Biochem. J. 453:393-399(2013).
RN   [26]
RP   VARIANT BCHE DEFICIENCY GLY-98.
RX   PubMed=2915989; DOI=10.1073/pnas.86.3.953;
RA   McGuire M.C., Nogueira C.P., Bartels C.F., Lightstone H., Hajra A.,
RA   van der Spek A.F.L., Lockridge O., la Du B.N.;
RT   "Identification of the structural mutation responsible for the
RT   dibucaine-resistant (atypical) variant form of human serum
RT   cholinesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:953-957(1989).
RN   [27]
RP   VARIANT BCHE DEFICIENCY VAL-525.
RX   PubMed=1349196;
RA   Bartels C.F., James K., La Du B.N.;
RT   "DNA mutations associated with the human butyrylcholinesterase J-
RT   variant.";
RL   Am. J. Hum. Genet. 50:1104-1114(1992).
RN   [28]
RP   VARIANTS BCHE DEFICIENCY MET-271 AND VAL-418.
RX   PubMed=1415224;
RA   Nogueira C.P., Bartels C.F., McGuire M.C., Adkins S., Lubrano T.,
RA   Rubinstein H.M., Lightstone H., Van Der Spek A.F.L., Lockridge O.,
RA   La Du B.N.;
RT   "Identification of two different point mutations associated with the
RT   fluoride-resistant phenotype for human butyrylcholinesterase.";
RL   Am. J. Hum. Genet. 51:821-828(1992).
RN   [29]
RP   VARIANT BCHE DEFICIENCY ARG-393.
RX   PubMed=1611188;
RA   Hada T., Muratani K., Ohue T., Imanishi H., Moriwaki Y., Itoh M.,
RA   Amuro Y., Higashino K.;
RT   "A variant serum cholinesterase and a confirmed point mutation at Gly-
RT   365 to Arg found in a patient with liver cirrhosis.";
RL   Intern. Med. 31:357-362(1992).
RN   [30]
RP   VARIANTS BCHE DEFICIENCY GLY-98 AND MET-170.
RX   PubMed=1306123;
RA   Jensen F.S., Bartels C.F., La Du B.N.;
RT   "Structural basis of the butyrylcholinesterase H-variant segregating
RT   in two Danish families.";
RL   Pharmacogenetics 2:234-240(1992).
RN   [31]
RP   VARIANTS BCHE DEFICIENCY PRO-278; ARG-393; SER-446; CYS-543 AND
RP   THR-567.
RX   PubMed=7634491; DOI=10.1016/0009-8981(95)06014-1;
RA   Maekawa M., Sudo K., Kanno T., Kotani K., Dey D.C., Ishikawa J.,
RA   Izumi M., Etoh K.;
RT   "Genetic basis of the silent phenotype of serum butyrylcholinesterase
RT   in three compound heterozygotes.";
RL   Clin. Chim. Acta 235:41-57(1995).
RN   [32]
RP   VARIANT BCHE DEFICIENCY ILE-358.
RX   PubMed=8680411; DOI=10.1002/humu.1380060411;
RA   Iida S., Kinoshita M., Fujii H., Moriyama Y., Nakamura Y., Yura N.,
RA   Moriwaki K.;
RT   "Mutations of human butyrylcholinesterase gene in a family with
RT   hypocholinesterasemia.";
RL   Hum. Mutat. 6:349-351(1995).
RN   [33]
RP   VARIANTS BCHE DEFICIENCY CYS-61; SER-65; PHE-153; GLU-198; GLY-226;
RP   THR-229; ARG-499 AND LEU-546, AND CHARACTERIZATION OF VARIANTS BCHE
RP   DEFICIENCY SER-65; PHE-153; GLU-198; ARG-499 AND LEU-546.
RX   PubMed=8554068;
RA   Primo-Parmo S.L., Bartels C.F., Wiersema B., van der Spek A.F.L.,
RA   Innis J.W., La Du B.N.;
RT   "Characterization of 12 silent alleles of the human
RT   butyrylcholinesterase (BCHE) gene.";
RL   Am. J. Hum. Genet. 58:52-64(1996).
RN   [34]
RP   VARIANT BCHE DEFICIENCY CYS-156.
RX   PubMed=9543549; DOI=10.1017/S0003480097006520;
RA   Hidaka K., Iuchi I., Tomita M., Watanabe Y., Minatogawa Y.,
RA   Iwasaki K., Gotoh K., Shimizu C.;
RT   "Genetic analysis of a Japanese patient with butyrylcholinesterase
RT   deficiency.";
RL   Ann. Hum. Genet. 61:491-496(1997).
RN   [35]
RP   VARIANT BUTYRYLCHOLINESTERASE DEFICIENCY ILE-358.
RX   PubMed=9388484; DOI=10.1006/bbrc.1997.7658;
RA   Sudo K., Maekawa M., Akizuki S., Magara T., Ogasawara H., Tanaka T.;
RT   "Human butyrylcholinesterase L330I mutation belongs to a fluoride-
RT   resistant gene, by expression in human fetal kidney cells.";
RL   Biochem. Biophys. Res. Commun. 240:372-375(1997).
RN   [36]
RP   VARIANTS BCHE DEFICIENCY ILE-32 DEL; MET-52; SER-128; PRO-278;
RP   ARG-295; ILE-358; ARG-393; SER-446; CYS-543 AND THR-567.
RX   PubMed=9191541;
RA   Maekawa M., Sudo K., Dey D.C., Ishikawa J., Izumi M., Kotani K.,
RA   Kanno T.;
RT   "Genetic mutations of butyrylcholine esterase identified from
RT   phenotypic abnormalities in Japan.";
RL   Clin. Chem. 43:924-929(1997).
RN   [37]
RP   VARIANTS BCHE DEFICIENCY GLY-98 AND ASP-143.
RX   PubMed=9110359;
RA   Primo-Parmo S.L., Lightstone H., La Du B.N.;
RT   "Characterization of an unstable variant (BChE115D) of human
RT   butyrylcholinesterase.";
RL   Pharmacogenetics 7:27-34(1997).
RN   [38]
RP   VARIANT BCHE DEFICIENCY VAL-227.
RX   PubMed=9694584; DOI=10.1016/S0009-8981(98)00058-8;
RA   Sakamoto N., Hidaka K., Fujisawa T., Maeda M., Iuchi I.;
RT   "Identification of a point mutation associated with a silent phenotype
RT   of human serum butyrylcholinesterase - a case of familial
RT   cholinesterasemia.";
RL   Clin. Chim. Acta 274:159-166(1998).
RN   [39]
RP   VARIANTS BCHE DEFICIENCY ILE-358; ARG-393 AND CYS-543.
RX   PubMed=10404729; DOI=10.1016/S0009-8981(99)00030-3;
RA   Asanuma K., Yagihashi A., Uehara N., Kida T., Watanabe N.;
RT   "Three point mutations of human butyrylcholinesterase in a Japanese
RT   family and the alterations of three-dimensional structure.";
RL   Clin. Chim. Acta 283:33-42(1999).
RN   [40]
RP   VARIANTS BCHE DEFICIENCY GLY-98; HIS-98; MET-271 AND THR-567.
RX   PubMed=11928765; DOI=10.1258/0004563021901775;
RA   Boeck A.T., Fry D.L., Sastre A., Lockridge O.;
RT   "Naturally occurring mutation, Asp70His, in human
RT   butyrylcholinesterase.";
RL   Ann. Clin. Biochem. 39:154-156(2002).
RN   [41]
RP   VARIANTS BCHE DEFICIENCY ILE-56; TYR-124; CYS-414 AND LYS-488.
RX   PubMed=12881446; DOI=10.1373/49.8.1297;
RA   Yen T., Nightingale B.N., Burns J.C., Sullivan D.R., Stewart P.M.;
RT   "Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine
RT   apnea in an Australian population.";
RL   Clin. Chem. 49:1297-1308(2003).
RN   [42]
RP   VARIANTS BCHE DEFICIENCY CYS-414 AND LEU-502.
RX   PubMed=15563885; DOI=10.1016/j.cccn.2004.09.004;
RA   On-Kei Chan A., Lam C.-W., Tong S.-F., Man Tung C., Yung K.,
RA   Chan Y.-W., Au K.-M., Yuen Y.-P., Hung C.-T., Ng K.-P., Shek C.-C.;
RT   "Novel mutations in the BCHE gene in patients with no
RT   butyrylcholinesterase activity.";
RL   Clin. Chim. Acta 351:155-159(2005).
RN   [43]
RP   VARIANT MET-127, AND VARIANTS BCHE DEFICIENCY GLY-98; ARG-103 AND
RP   ASP-118.
RX   PubMed=15781196; DOI=10.1016/j.ymgme.2004.12.005;
RA   Souza R.L., Mikami L.R., Maegawa R.O., Chautard-Freire-Maia E.A.;
RT   "Four new mutations in the BCHE gene of human butyrylcholinesterase in
RT   a Brazilian blood donor sample.";
RL   Mol. Genet. Metab. 84:349-353(2005).
RN   [44]
RP   VARIANT BCHE DEFICIENCY PRO-335, AND CHARACTERIZATION OF VARIANT BCHE
RP   DEFICIENCY PRO-335.
RX   PubMed=16788378; DOI=10.1097/01.fpc.0000197464.37211.77;
RA   Manoharan I., Wieseler S., Layer P.G., Lockridge O., Boopathy R.;
RT   "Naturally occurring mutation Leu307Pro of human butyrylcholinesterase
RT   in the Vysya community of India.";
RL   Pharmacogenet. Genomics 16:461-468(2006).
RN   [45]
RP   CHARACTERIZATION OF VARIANT MET-127, AND CHARACTERIZATION OF VARIANTS
RP   BCHE DEFICIENCY ARG-103 AND ASP-118.
RX   PubMed=17700357; DOI=10.1097/01.fpc.0000236333.49422.86;
RA   Mikami L.R., Wieseler S., Souza R.L., Schopfer L.M., Lockridge O.,
RA   Chautard-Freire-Maia E.A.;
RT   "Expression of three naturally occurring genetic variants (G75R, E90D,
RT   I99M) of the BCHE gene of human butyrylcholinesterase.";
RL   Pharmacogenet. Genomics 17:681-685(2007).
RN   [46]
RP   VARIANT BCHE DEFICIENCY ASP-356.
RX   PubMed=18075469; DOI=10.1097/FPC.0b013e3282f06646;
RA   Gaetke M.R., Bundgaard J.R., Viby-Mogensen J.;
RT   "Two novel mutations in the BCHE gene in patients with prolonged
RT   duration of action of mivacurium or succinylcholine during
RT   anaesthesia.";
RL   Pharmacogenet. Genomics 17:995-999(2007).
RN   [47]
RP   VARIANT BCHE DEFICIENCY CYS-361, VARIANTS ARG-40; MET-322 AND TRP-498,
RP   CHARACTERIZATION OF VARIANT BCHE DEFICIENCY CYS-361, AND
RP   CHARACTERIZATION OF VARIANTS ARG-40; MET-322 AND TRP-498.
RX   PubMed=18300943; DOI=10.1097/FPC.0b013e3282f5107e;
RA   Mikami L.R., Wieseler S., Souza R.L., Schopfer L.M., Nachon F.,
RA   Lockridge O., Chautard-Freire-Maia E.A.;
RT   "Five new naturally occurring mutations of the BCHE gene and
RT   frequencies of 12 butyrylcholinesterase alleles in a Brazilian
RT   population.";
RL   Pharmacogenet. Genomics 18:213-218(2008).
RN   [48]
RP   VARIANTS BCHE DEFICIENCY VAL-62 AND GLY-98, AND CHARACTERIZATION OF
RP   VARIANTS BCHE DEFICIENCY VAL-62 AND GLY-98.
RX   PubMed=25264279; DOI=10.1016/j.bcp.2014.09.014;
RA   Delacour H., Lushchekina S., Mabboux I., Ceppa F., Masson P.,
RA   Schopfer L.M., Lockridge O.;
RT   "Characterization of a novel butyrylcholinesterase point mutation
RT   (p.Ala34Val), 'silent' with mivacurium.";
RL   Biochem. Pharmacol. 92:476-483(2014).
CC   -!- FUNCTION: Esterase with broad substrate specificity. Contributes
CC       to the inactivation of the neurotransmitter acetylcholine. Can
CC       degrade neurotoxic organophosphate esters.
CC       {ECO:0000269|PubMed:19452557, ECO:0000269|PubMed:19542320}.
CC   -!- CATALYTIC ACTIVITY: An acylcholine + H(2)O = choline + a
CC       carboxylate. {ECO:0000269|PubMed:19368529,
CC       ECO:0000269|PubMed:19452557}.
CC   -!- ENZYME REGULATION: Inhibited by mercury. Inhibited by Tabun. Tabun
CC       forms a covalent adduct with Ser-226 that becomes irreversible
CC       upon aging. {ECO:0000269|PubMed:17355286,
CC       ECO:0000269|PubMed:18975951, ECO:0000269|PubMed:19368529}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18.0 uM for butyrylthiocholine (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25054547};
CC   -!- SUBUNIT: Homotetramer; disulfide-linked. Dimer of dimers.
CC       {ECO:0000269|PubMed:12869558, ECO:0000269|PubMed:15667209,
CC       ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
CC       ECO:0000269|PubMed:18975951, ECO:0000269|PubMed:19368529,
CC       ECO:0000269|PubMed:19542320, ECO:0000269|PubMed:3115973}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-7936069, EBI-7936069;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19368529,
CC       ECO:0000269|PubMed:19542320}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       Present in most cells except erythrocytes.
CC       {ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:19542320}.
CC   -!- PTM: N-glycosylated. No other PTM detected (PubMed:20946535). The
CC       major N-glycan structures are of the complex diantennary type with
CC       1 and 2 N-acetylneuraminic acid molecules (Neu5Ac) making up
CC       approximately 33% and 47% of the total N-glycans, respectively.
CC       Only low amounts of fucosylated diantennary N-glycans are detected
CC       (approximately 2%). Triantennary N-glycans with or without fucose
CC       amount to approximately 13%, whereas 5% of the total N-glycans are
CC       of the oligomannosidic or hybrid type.
CC       {ECO:0000269|PubMed:12869558, ECO:0000269|PubMed:14760718,
CC       ECO:0000269|PubMed:15667209, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:17355286, ECO:0000269|PubMed:17768338,
CC       ECO:0000269|PubMed:18203274, ECO:0000269|PubMed:18975951,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19368529, ECO:0000269|PubMed:20946535}.
CC   -!- DISEASE: Butyrylcholinesterase deficiency (BChE deficiency)
CC       [MIM:177400]: A metabolic disorder characterized by prolonged
CC       apnea after the use of certain anesthetic drugs, including the
CC       muscle relaxants succinylcholine or mivacurium and other ester
CC       local anesthetics. The duration of the prolonged apnea varies
CC       significantly depending on the extent of the enzyme deficiency.
CC       {ECO:0000269|PubMed:10404729, ECO:0000269|PubMed:11928765,
CC       ECO:0000269|PubMed:12881446, ECO:0000269|PubMed:1306123,
CC       ECO:0000269|PubMed:1349196, ECO:0000269|PubMed:1415224,
CC       ECO:0000269|PubMed:15563885, ECO:0000269|PubMed:15781196,
CC       ECO:0000269|PubMed:1611188, ECO:0000269|PubMed:16788378,
CC       ECO:0000269|PubMed:17700357, ECO:0000269|PubMed:18075469,
CC       ECO:0000269|PubMed:18300943, ECO:0000269|PubMed:25054547,
CC       ECO:0000269|PubMed:25264279, ECO:0000269|PubMed:2915989,
CC       ECO:0000269|PubMed:7634491, ECO:0000269|PubMed:8554068,
CC       ECO:0000269|PubMed:8680411, ECO:0000269|PubMed:9110359,
CC       ECO:0000269|PubMed:9191541, ECO:0000269|PubMed:9388484,
CC       ECO:0000269|PubMed:9543549, ECO:0000269|PubMed:9694584}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the type-B carboxylesterase/lipase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32391; AAA99296.1; -; Genomic_DNA.
DR   EMBL; M32389; AAA99296.1; JOINED; Genomic_DNA.
DR   EMBL; M32390; AAA99296.1; JOINED; Genomic_DNA.
DR   EMBL; M16541; AAA98113.1; -; mRNA.
DR   EMBL; M16474; AAA52015.1; -; mRNA.
DR   EMBL; AK292063; BAF84752.1; -; mRNA.
DR   EMBL; BC018141; AAH18141.1; -; mRNA.
DR   CCDS; CCDS3198.1; -.
DR   PIR; A33769; ACHU.
DR   RefSeq; NP_000046.1; NM_000055.3.
DR   UniGene; Hs.420483; -.
DR   PDB; 1EHO; Model; -; A=30-560.
DR   PDB; 1EHQ; Model; -; A=30-560.
DR   PDB; 1KCJ; Model; -; A=30-560.
DR   PDB; 1P0I; X-ray; 2.00 A; A=29-557.
DR   PDB; 1P0M; X-ray; 2.38 A; A=29-557.
DR   PDB; 1P0P; X-ray; 2.30 A; A=29-557.
DR   PDB; 1P0Q; X-ray; 2.43 A; A=29-557.
DR   PDB; 1XLU; X-ray; 2.20 A; A=29-557.
DR   PDB; 1XLV; X-ray; 2.25 A; A=29-557.
DR   PDB; 1XLW; X-ray; 2.10 A; A=29-557.
DR   PDB; 2J4C; X-ray; 2.75 A; A=29-557.
DR   PDB; 2PM8; X-ray; 2.80 A; A/B=29-602.
DR   PDB; 2WID; X-ray; 2.30 A; A=29-557.
DR   PDB; 2WIF; X-ray; 2.25 A; A=29-557.
DR   PDB; 2WIG; X-ray; 2.15 A; A=29-557.
DR   PDB; 2WIJ; X-ray; 2.10 A; A=29-557.
DR   PDB; 2WIK; X-ray; 2.10 A; A=29-557.
DR   PDB; 2WIL; X-ray; 3.10 A; A/B=29-557.
DR   PDB; 2WSL; X-ray; 2.00 A; A=29-557.
DR   PDB; 2XMB; X-ray; 2.10 A; A=29-557.
DR   PDB; 2XMC; X-ray; 2.40 A; A=29-557.
DR   PDB; 2XMD; X-ray; 2.30 A; A=29-557.
DR   PDB; 2XMG; X-ray; 2.70 A; A=29-557.
DR   PDB; 2XQF; X-ray; 2.10 A; A=31-557.
DR   PDB; 2XQG; X-ray; 2.30 A; A=31-557.
DR   PDB; 2XQI; X-ray; 2.60 A; A=31-557.
DR   PDB; 2XQJ; X-ray; 2.40 A; A=31-557.
DR   PDB; 2XQK; X-ray; 2.40 A; A=31-557.
DR   PDB; 2Y1K; X-ray; 2.50 A; A=29-557.
DR   PDB; 3DJY; X-ray; 2.10 A; A=29-557.
DR   PDB; 3DKK; X-ray; 2.31 A; A=29-557.
DR   PDB; 3O9M; X-ray; 2.98 A; A/B=29-602.
DR   PDB; 4AQD; X-ray; 2.50 A; A/B=29-557.
DR   PDB; 4AXB; X-ray; 2.40 A; A=31-557.
DR   PDB; 4B0O; X-ray; 2.35 A; A=29-557.
DR   PDB; 4B0P; X-ray; 2.50 A; A=29-557.
DR   PDB; 4BBZ; X-ray; 2.70 A; A=29-557.
DR   PDB; 4BDS; X-ray; 2.10 A; A=29-557.
DR   PDB; 4TPK; X-ray; 2.70 A; A/B=1-602.
DR   PDB; 4XII; X-ray; 2.70 A; A/B=29-572.
DR   PDB; 5DYT; X-ray; 2.55 A; A/B=28-557.
DR   PDB; 5DYW; X-ray; 2.50 A; A/B=28-557.
DR   PDB; 5DYY; X-ray; 2.65 A; A/B=28-557.
DR   PDB; 5K5E; X-ray; 2.80 A; A/B=29-557.
DR   PDB; 5LKR; X-ray; 2.52 A; A/B=29-602.
DR   PDBsum; 1EHO; -.
DR   PDBsum; 1EHQ; -.
DR   PDBsum; 1KCJ; -.
DR   PDBsum; 1P0I; -.
DR   PDBsum; 1P0M; -.
DR   PDBsum; 1P0P; -.
DR   PDBsum; 1P0Q; -.
DR   PDBsum; 1XLU; -.
DR   PDBsum; 1XLV; -.
DR   PDBsum; 1XLW; -.
DR   PDBsum; 2J4C; -.
DR   PDBsum; 2PM8; -.
DR   PDBsum; 2WID; -.
DR   PDBsum; 2WIF; -.
DR   PDBsum; 2WIG; -.
DR   PDBsum; 2WIJ; -.
DR   PDBsum; 2WIK; -.
DR   PDBsum; 2WIL; -.
DR   PDBsum; 2WSL; -.
DR   PDBsum; 2XMB; -.
DR   PDBsum; 2XMC; -.
DR   PDBsum; 2XMD; -.
DR   PDBsum; 2XMG; -.
DR   PDBsum; 2XQF; -.
DR   PDBsum; 2XQG; -.
DR   PDBsum; 2XQI; -.
DR   PDBsum; 2XQJ; -.
DR   PDBsum; 2XQK; -.
DR   PDBsum; 2Y1K; -.
DR   PDBsum; 3DJY; -.
DR   PDBsum; 3DKK; -.
DR   PDBsum; 3O9M; -.
DR   PDBsum; 4AQD; -.
DR   PDBsum; 4AXB; -.
DR   PDBsum; 4B0O; -.
DR   PDBsum; 4B0P; -.
DR   PDBsum; 4BBZ; -.
DR   PDBsum; 4BDS; -.
DR   PDBsum; 4TPK; -.
DR   PDBsum; 4XII; -.
DR   PDBsum; 5DYT; -.
DR   PDBsum; 5DYW; -.
DR   PDBsum; 5DYY; -.
DR   PDBsum; 5K5E; -.
DR   PDBsum; 5LKR; -.
DR   ProteinModelPortal; P06276; -.
DR   SMR; P06276; -.
DR   BioGrid; 107064; 30.
DR   DIP; DIP-46476N; -.
DR   IntAct; P06276; 1.
DR   STRING; 9606.ENSP00000264381; -.
DR   BindingDB; P06276; -.
DR   ChEMBL; CHEMBL1914; -.
DR   DrugBank; DB08200; (1R)-MENTHYL HEXYL PHOSPHONATE GROUP.
DR   DrugBank; DB08201; (1S)-MENTHYL HEXYL PHOSPHONATE GROUP.
DR   DrugBank; DB03814; 2-(N-Morpholino)-Ethanesulfonic Acid.
DR   DrugBank; DB03672; 9-N-Phenylmethylamino-Tacrine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB01122; Ambenonium.
DR   DrugBank; DB01408; Bambuterol.
DR   DrugBank; DB03568; Butanoic Acid.
DR   DrugBank; DB04250; Butyrylthiocholine.
DR   DrugBank; DB06774; Capsaicin.
DR   DrugBank; DB01161; Chloroprocaine.
DR   DrugBank; DB00856; Chlorphenesin.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00122; Choline.
DR   DrugBank; DB00527; Cinchocaine.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB04920; Clevidipine.
DR   DrugBank; DB00979; Cyclopentolate.
DR   DrugBank; DB01245; Decamethonium.
DR   DrugBank; DB00944; Demecarium.
DR   DrugBank; DB00711; Diethylcarbamazine.
DR   DrugBank; DB02811; Diethylphosphono Group.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB07681; DODECANESULFONATE ION.
DR   DrugBank; DB01135; Doxacurium chloride.
DR   DrugBank; DB01395; Drospirenone.
DR   DrugBank; DB01525; Ecgonine.
DR   DrugBank; DB01057; Echothiophate.
DR   DrugBank; DB01010; Edrophonium.
DR   DrugBank; DB01364; Ephedrine.
DR   DrugBank; DB00392; Ethopropazine.
DR   DrugBank; DB03822; Ethyl Dihydrogen Phosphate.
DR   DrugBank; DB08658; ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE.
DR   DrugBank; DB00674; Galantamine.
DR   DrugBank; DB06756; Glycine betaine.
DR   DrugBank; DB00941; Hexafluronium.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00677; Isoflurophate.
DR   DrugBank; DB00772; Malathion.
DR   DrugBank; DB00358; Mefloquine.
DR   DrugBank; DB02845; Methylphosphinic Acid.
DR   DrugBank; DB08893; Mirabegron.
DR   DrugBank; DB01226; Mivacurium.
DR   DrugBank; DB04251; Monoisopropyl Ester Phosphonic Acid Group.
DR   DrugBank; DB01400; Neostigmine.
DR   DrugBank; DB00585; Nizatidine.
DR   DrugBank; DB00892; Oxybuprocaine.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00082; Pegvisomant.
DR   DrugBank; DB00183; Pentagastrin.
DR   DrugBank; DB00790; Perindopril.
DR   DrugBank; DB04892; Phenserine.
DR   DrugBank; DB01338; Pipecuronium.
DR   DrugBank; DB00733; Pralidoxime.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB00545; Pyridostigmine.
DR   DrugBank; DB00178; Ramipril.
DR   DrugBank; DB05386; recombinant human GM-CSF.
DR   DrugBank; DB00989; Rivastigmine.
DR   DrugBank; DB05875; substance P.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00391; Sulpiride.
DR   DrugBank; DB00382; Tacrine.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB00620; Triamcinolone.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB01116; Trimethaphan.
DR   GuidetoPHARMACOLOGY; 2471; -.
DR   ESTHER; human-BCHE; BCHE.
DR   MEROPS; S09.980; -.
DR   iPTMnet; P06276; -.
DR   PhosphoSitePlus; P06276; -.
DR   BioMuta; BCHE; -.
DR   DMDM; 116353; -.
DR   EPD; P06276; -.
DR   MaxQB; P06276; -.
DR   PaxDb; P06276; -.
DR   PeptideAtlas; P06276; -.
DR   PRIDE; P06276; -.
DR   DNASU; 590; -.
DR   Ensembl; ENST00000264381; ENSP00000264381; ENSG00000114200.
DR   GeneID; 590; -.
DR   KEGG; hsa:590; -.
DR   UCSC; uc003fem.5; human.
DR   CTD; 590; -.
DR   DisGeNET; 590; -.
DR   GeneCards; BCHE; -.
DR   HGNC; HGNC:983; BCHE.
DR   HPA; HPA001560; -.
DR   MalaCards; BCHE; -.
DR   MIM; 177400; gene+phenotype.
DR   neXtProt; NX_P06276; -.
DR   OpenTargets; ENSG00000114200; -.
DR   Orphanet; 132; Butyrylcholinesterase deficiency.
DR   Orphanet; 413693; Curariform drugs toxicity.
DR   PharmGKB; PA25294; -.
DR   eggNOG; KOG4389; Eukaryota.
DR   eggNOG; COG2272; LUCA.
DR   GeneTree; ENSGT00760000118946; -.
DR   HOVERGEN; HBG008839; -.
DR   InParanoid; P06276; -.
DR   KO; K01050; -.
DR   OMA; FLGSEMW; -.
DR   OrthoDB; EOG091G0I4G; -.
DR   PhylomeDB; P06276; -.
DR   TreeFam; TF315470; -.
DR   BRENDA; 3.1.1.8; 2681.
DR   Reactome; R-HSA-112311; Neurotransmitter Clearance In The Synaptic Cleft.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   SABIO-RK; P06276; -.
DR   ChiTaRS; BCHE; human.
DR   EvolutionaryTrace; P06276; -.
DR   GeneWiki; Butyrylcholinesterase; -.
DR   GenomeRNAi; 590; -.
DR   PRO; PR:P06276; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114200; -.
DR   CleanEx; HS_BCHE; -.
DR   ExpressionAtlas; P06276; baseline and differential.
DR   Genevisible; P06276; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0005641; C:nuclear envelope lumen; IEA:Ensembl.
DR   GO; GO:0003990; F:acetylcholinesterase activity; ISS:UniProtKB.
DR   GO; GO:0001540; F:beta-amyloid binding; NAS:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; NAS:UniProtKB.
DR   GO; GO:0033265; F:choline binding; IEA:Ensembl.
DR   GO; GO:0004104; F:cholinesterase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; NAS:UniProtKB.
DR   GO; GO:0016788; F:hydrolase activity, acting on ester bonds; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019695; P:choline metabolic process; IEA:Ensembl.
DR   GO; GO:0050783; P:cocaine metabolic process; TAS:UniProtKB.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0050805; P:negative regulation of synaptic transmission; IEA:Ensembl.
DR   GO; GO:0014016; P:neuroblast differentiation; IEA:Ensembl.
DR   GO; GO:0043279; P:response to alkaloid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR014788; AChE_tetra.
DR   InterPro; IPR002018; CarbesteraseB.
DR   InterPro; IPR019826; Carboxylesterase_B_AS.
DR   InterPro; IPR019819; Carboxylesterase_B_CS.
DR   InterPro; IPR000997; Cholinesterase.
DR   Pfam; PF08674; AChE_tetra; 1.
DR   Pfam; PF00135; COesterase; 1.
DR   PRINTS; PR00878; CHOLNESTRASE.
DR   ProDom; PD415333; AChE_tetra; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS00122; CARBOXYLESTERASE_B_1; 1.
DR   PROSITE; PS00941; CARBOXYLESTERASE_B_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hydrolase;
KW   Phosphoprotein; Polymorphism; Reference proteome; Secreted;
KW   Serine esterase; Sialic acid; Signal.
FT   SIGNAL        1     28       {ECO:0000269|PubMed:20946535,
FT                                ECO:0000269|PubMed:3542989}.
FT   CHAIN        29    602       Cholinesterase.
FT                                /FTId=PRO_0000008613.
FT   REGION      144    145       Substrate binding.
FT   ACT_SITE    226    226       Acyl-ester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10039,
FT                                ECO:0000269|PubMed:12869558}.
FT   ACT_SITE    353    353       Charge relay system.
FT                                {ECO:0000269|PubMed:12869558}.
FT   ACT_SITE    466    466       Charge relay system.
FT                                {ECO:0000269|PubMed:12869558}.
FT   BINDING     110    110       Tacrine. {ECO:0000244|PDB:4BDS}.
FT   BINDING     466    466       Tacrine; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:4BDS}.
FT   MOD_RES     226    226       Phosphoserine.
FT                                {ECO:0000269|PubMed:22444575}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18203274}.
FT   CARBOHYD     85     85       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12869558,
FT                                ECO:0000269|PubMed:15667209,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17355286,
FT                                ECO:0000269|PubMed:17768338,
FT                                ECO:0000269|PubMed:18203274,
FT                                ECO:0000269|PubMed:18975951,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12869558,
FT                                ECO:0000269|PubMed:15667209,
FT                                ECO:0000269|PubMed:17355286,
FT                                ECO:0000269|PubMed:17768338,
FT                                ECO:0000269|PubMed:18203274,
FT                                ECO:0000269|PubMed:18975951,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    269    269       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12869558,
FT                                ECO:0000269|PubMed:15667209,
FT                                ECO:0000269|PubMed:17355286,
FT                                ECO:0000269|PubMed:18203274,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    284    284       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:18203274,
FT                                ECO:0000269|PubMed:18975951,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    369    369       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12869558,
FT                                ECO:0000269|PubMed:15667209,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17355286,
FT                                ECO:0000269|PubMed:17768338,
FT                                ECO:0000269|PubMed:18203274,
FT                                ECO:0000269|PubMed:18975951,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    483    483       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18203274}.
FT   CARBOHYD    509    509       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:3542989}.
FT   CARBOHYD    513    513       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12869558,
FT                                ECO:0000269|PubMed:15667209,
FT                                ECO:0000269|PubMed:17355286,
FT                                ECO:0000269|PubMed:17768338,
FT                                ECO:0000269|PubMed:18975951,
FT                                ECO:0000269|PubMed:19368529,
FT                                ECO:0000269|PubMed:23679855}.
FT   CARBOHYD    514    514       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:3542989}.
FT   DISULFID     93    120
FT   DISULFID    280    291
FT   DISULFID    428    547
FT   DISULFID    599    599       Interchain.
FT   VARIANT      32     32       Missing (in BChE deficiency).
FT                                {ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040011.
FT   VARIANT      40     40       K -> R (rare polymorphism; does not
FT                                affect enzymatic activity;
FT                                dbSNP:rs116047990).
FT                                {ECO:0000269|PubMed:18300943}.
FT                                /FTId=VAR_072094.
FT   VARIANT      52     52       T -> M (in BChE deficiency;
FT                                dbSNP:rs56309853).
FT                                {ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040012.
FT   VARIANT      56     56       F -> I (in BChE deficiency;
FT                                dbSNP:rs531738678).
FT                                {ECO:0000269|PubMed:12881446}.
FT                                /FTId=VAR_040013.
FT   VARIANT      61     61       Y -> C (in BChE deficiency; enzymatically
FT                                inactive in the plasma;
FT                                dbSNP:rs116097205).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040014.
FT   VARIANT      62     62       A -> V (in BChE deficiency; reduced
FT                                enzyme activity with butyrylthiocholine
FT                                as substrate; inactive with
FT                                butyrylthiocholine as substrate in the
FT                                presence of G-98; 2-fold lower affinity
FT                                for butyrylthiocholine; 10-fold lower
FT                                affinity for butyrylthiocholine in the
FT                                presence of G-98).
FT                                {ECO:0000269|PubMed:25264279}.
FT                                /FTId=VAR_072730.
FT   VARIANT      65     65       P -> S (in BChE deficiency; seems to
FT                                cause reduced expression of the protein;
FT                                dbSNP:rs148170012).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040015.
FT   VARIANT      98     98       D -> G (in BChE deficiency; atypical
FT                                form; reduced enzyme activity with
FT                                butyrylthiocholine as substrate; inactive
FT                                with butyrylthiocholine as substrate in
FT                                the presence of V-62; 2-fold lower
FT                                affinity for butyrylthiocholine; 10-fold
FT                                lower affinity for butyrylthiocholine in
FT                                the presence of V-62 or at homozygosity;
FT                                dbSNP:rs1799807).
FT                                {ECO:0000269|PubMed:11928765,
FT                                ECO:0000269|PubMed:1306123,
FT                                ECO:0000269|PubMed:15781196,
FT                                ECO:0000269|PubMed:25264279,
FT                                ECO:0000269|PubMed:2915989,
FT                                ECO:0000269|PubMed:9110359}.
FT                                /FTId=VAR_002360.
FT   VARIANT      98     98       D -> H (in BChE deficiency).
FT                                {ECO:0000269|PubMed:11928765}.
FT                                /FTId=VAR_040016.
FT   VARIANT     103    103       G -> R (in BChE deficiency; reduced
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:15781196,
FT                                ECO:0000269|PubMed:17700357}.
FT                                /FTId=VAR_072095.
FT   VARIANT     118    118       E -> D (in BChE deficiency; the mutant
FT                                undergoes rapid degradation).
FT                                {ECO:0000269|PubMed:15781196,
FT                                ECO:0000269|PubMed:17700357}.
FT                                /FTId=VAR_072096.
FT   VARIANT     124    124       N -> Y (in BChE deficiency).
FT                                {ECO:0000269|PubMed:12881446}.
FT                                /FTId=VAR_040017.
FT   VARIANT     127    127       I -> M (rare polymorphism; does not
FT                                affect enzyme activity;
FT                                dbSNP:rs755600722).
FT                                {ECO:0000269|PubMed:15781196,
FT                                ECO:0000269|PubMed:17700357}.
FT                                /FTId=VAR_072097.
FT   VARIANT     128    128       P -> S (in BChE deficiency;
FT                                dbSNP:rs3732880).
FT                                {ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040018.
FT   VARIANT     143    143       G -> D (in BChE deficiency;
FT                                dbSNP:rs201820739).
FT                                {ECO:0000269|PubMed:9110359}.
FT                                /FTId=VAR_040019.
FT   VARIANT     153    153       L -> F (in BChE deficiency; seems to
FT                                cause reduced expression of the protein;
FT                                dbSNP:rs747598704).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040020.
FT   VARIANT     156    156       Y -> C (in BChE deficiency;
FT                                dbSNP:rs121918558).
FT                                {ECO:0000269|PubMed:9543549}.
FT                                /FTId=VAR_040021.
FT   VARIANT     170    170       V -> M (in BChE deficiency; allele H
FT                                variant; dbSNP:rs527843566).
FT                                {ECO:0000269|PubMed:1306123}.
FT                                /FTId=VAR_040022.
FT   VARIANT     198    198       D -> E (in BChE deficiency; seems to
FT                                cause reduced expression of the protein;
FT                                dbSNP:rs781368801).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040023.
FT   VARIANT     226    226       S -> G (in BChE deficiency; enzymatically
FT                                inactive in the plasma;
FT                                dbSNP:rs370077923).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040024.
FT   VARIANT     227    227       A -> V (in BChE deficiency).
FT                                {ECO:0000269|PubMed:9694584}.
FT                                /FTId=VAR_040025.
FT   VARIANT     229    229       A -> T (in BChE deficiency; enzymatically
FT                                inactive in the plasma).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040026.
FT   VARIANT     232    232       V -> D (in BChE deficiency).
FT                                {ECO:0000269|PubMed:25054547}.
FT                                /FTId=VAR_072098.
FT   VARIANT     271    271       T -> M (in BChE deficiency; allele
FT                                fluoride-1; dbSNP:rs28933389).
FT                                {ECO:0000269|PubMed:11928765,
FT                                ECO:0000269|PubMed:1415224}.
FT                                /FTId=VAR_040027.
FT   VARIANT     278    278       T -> P (in BChE deficiency).
FT                                {ECO:0000269|PubMed:7634491,
FT                                ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040028.
FT   VARIANT     283    283       E -> D (in dbSNP:rs16849700).
FT                                /FTId=VAR_040029.
FT   VARIANT     295    295       K -> R (in BChE deficiency;
FT                                dbSNP:rs115624085).
FT                                {ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040030.
FT   VARIANT     322    322       V -> M (rare polymorphism; does not
FT                                affect enzymatic activity;
FT                                dbSNP:rs754644618).
FT                                {ECO:0000269|PubMed:18300943}.
FT                                /FTId=VAR_072099.
FT   VARIANT     335    335       L -> P (in BChE deficiency; expressed at
FT                                very low level; dbSNP:rs104893684).
FT                                {ECO:0000269|PubMed:16788378}.
FT                                /FTId=VAR_040031.
FT   VARIANT     356    356       A -> D (in BChE deficiency;
FT                                dbSNP:rs770337031).
FT                                {ECO:0000269|PubMed:18075469}.
FT                                /FTId=VAR_040032.
FT   VARIANT     358    358       L -> I (in BChE deficiency; BChE variant
FT                                form; fluoride-resistant;
FT                                dbSNP:rs121918557).
FT                                {ECO:0000269|PubMed:10404729,
FT                                ECO:0000269|PubMed:8680411,
FT                                ECO:0000269|PubMed:9191541,
FT                                ECO:0000269|PubMed:9388484}.
FT                                /FTId=VAR_002362.
FT   VARIANT     361    361       G -> C (in BChE deficiency; results in
FT                                20% of activity compared to wild-type).
FT                                {ECO:0000269|PubMed:18300943}.
FT                                /FTId=VAR_072100.
FT   VARIANT     393    393       G -> R (in BChE deficiency;
FT                                dbSNP:rs115129687).
FT                                {ECO:0000269|PubMed:10404729,
FT                                ECO:0000269|PubMed:1611188,
FT                                ECO:0000269|PubMed:7634491,
FT                                ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040033.
FT   VARIANT     414    414       R -> C (in BChE deficiency;
FT                                dbSNP:rs745364489).
FT                                {ECO:0000269|PubMed:12881446,
FT                                ECO:0000269|PubMed:15563885}.
FT                                /FTId=VAR_040034.
FT   VARIANT     418    418       G -> V (in BChE deficiency; allele
FT                                fluoride-2; dbSNP:rs28933390).
FT                                {ECO:0000269|PubMed:1415224}.
FT                                /FTId=VAR_040035.
FT   VARIANT     446    446       F -> S (in BChE deficiency).
FT                                {ECO:0000269|PubMed:7634491,
FT                                ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040036.
FT   VARIANT     488    488       E -> K (in BChE deficiency;
FT                                dbSNP:rs200998515).
FT                                {ECO:0000269|PubMed:12881446}.
FT                                /FTId=VAR_040037.
FT   VARIANT     498    498       R -> W (rare polymorphism; does not
FT                                affect enzymatic activity;
FT                                dbSNP:rs115017300).
FT                                {ECO:0000269|PubMed:18300943}.
FT                                /FTId=VAR_072101.
FT   VARIANT     499    499       W -> R (in BChE deficiency; seems to
FT                                cause reduced expression of the protein).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040038.
FT   VARIANT     502    502       F -> L (in BChE deficiency;
FT                                dbSNP:rs769316835).
FT                                {ECO:0000269|PubMed:15563885}.
FT                                /FTId=VAR_040039.
FT   VARIANT     525    525       E -> V (in BChE deficiency; allele J
FT                                variant; dbSNP:rs121918556).
FT                                {ECO:0000269|PubMed:1349196}.
FT                                /FTId=VAR_040040.
FT   VARIANT     543    543       R -> C (in BChE deficiency;
FT                                dbSNP:rs199660374).
FT                                {ECO:0000269|PubMed:10404729,
FT                                ECO:0000269|PubMed:7634491,
FT                                ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_040041.
FT   VARIANT     546    546       Q -> L (in BChE deficiency; seems to
FT                                cause reduced expression of the protein).
FT                                {ECO:0000269|PubMed:8554068}.
FT                                /FTId=VAR_040042.
FT   VARIANT     567    567       A -> T (in BChE deficiency; allele K
FT                                variant; with reduced enzyme activity;
FT                                dbSNP:rs1803274).
FT                                {ECO:0000269|PubMed:11928765,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:7634491,
FT                                ECO:0000269|PubMed:9191541}.
FT                                /FTId=VAR_002364.
FT   STRAND       33     36       {ECO:0000244|PDB:1P0I}.
FT   STRAND       39     42       {ECO:0000244|PDB:1P0I}.
FT   STRAND       44     48       {ECO:0000244|PDB:1P0I}.
FT   STRAND       51     60       {ECO:0000244|PDB:1P0I}.
FT   HELIX        67     69       {ECO:0000244|PDB:1P0I}.
FT   STRAND       82     85       {ECO:0000244|PDB:1P0I}.
FT   HELIX       105    108       {ECO:0000244|PDB:1P0I}.
FT   STRAND      116    118       {ECO:0000244|PDB:2XMB}.
FT   STRAND      122    130       {ECO:0000244|PDB:1P0I}.
FT   STRAND      133    141       {ECO:0000244|PDB:1P0I}.
FT   TURN        145    147       {ECO:0000244|PDB:1P0I}.
FT   HELIX       154    156       {ECO:0000244|PDB:1P0I}.
FT   HELIX       159    165       {ECO:0000244|PDB:1P0I}.
FT   STRAND      168    172       {ECO:0000244|PDB:1P0I}.
FT   HELIX       177    181       {ECO:0000244|PDB:1P0I}.
FT   STRAND      190    192       {ECO:0000244|PDB:2WSL}.
FT   HELIX       194    209       {ECO:0000244|PDB:1P0I}.
FT   HELIX       210    213       {ECO:0000244|PDB:1P0I}.
FT   STRAND      215    225       {ECO:0000244|PDB:1P0I}.
FT   HELIX       227    237       {ECO:0000244|PDB:1P0I}.
FT   HELIX       239    244       {ECO:0000244|PDB:1P0I}.
FT   STRAND      246    252       {ECO:0000244|PDB:1P0I}.
FT   TURN        258    260       {ECO:0000244|PDB:4BDS}.
FT   HELIX       264    277       {ECO:0000244|PDB:1P0I}.
FT   HELIX       285    292       {ECO:0000244|PDB:1P0I}.
FT   HELIX       297    304       {ECO:0000244|PDB:1P0I}.
FT   HELIX       305    307       {ECO:0000244|PDB:1P0I}.
FT   STRAND      308    310       {ECO:0000244|PDB:1P0I}.
FT   STRAND      324    326       {ECO:0000244|PDB:1P0I}.
FT   HELIX       331    336       {ECO:0000244|PDB:1P0I}.
FT   STRAND      345    350       {ECO:0000244|PDB:1P0I}.
FT   STRAND      352    354       {ECO:0000244|PDB:1P0P}.
FT   HELIX       355    358       {ECO:0000244|PDB:1P0I}.
FT   TURN        359    361       {ECO:0000244|PDB:1P0I}.
FT   STRAND      367    369       {ECO:0000244|PDB:4B0P}.
FT   HELIX       375    385       {ECO:0000244|PDB:1P0I}.
FT   STRAND      387    389       {ECO:0000244|PDB:2WSL}.
FT   HELIX       391    401       {ECO:0000244|PDB:1P0I}.
FT   TURN        405    408       {ECO:0000244|PDB:2WIK}.
FT   HELIX       412    425       {ECO:0000244|PDB:1P0I}.
FT   HELIX       427    438       {ECO:0000244|PDB:1P0I}.
FT   TURN        439    441       {ECO:0000244|PDB:1P0I}.
FT   STRAND      444    449       {ECO:0000244|PDB:1P0I}.
FT   HELIX       460    462       {ECO:0000244|PDB:1P0I}.
FT   TURN        466    469       {ECO:0000244|PDB:1P0I}.
FT   HELIX       470    473       {ECO:0000244|PDB:1P0I}.
FT   HELIX       476    478       {ECO:0000244|PDB:1P0I}.
FT   HELIX       480    482       {ECO:0000244|PDB:2WSL}.
FT   HELIX       486    505       {ECO:0000244|PDB:1P0I}.
FT   TURN        511    514       {ECO:0000244|PDB:1P0I}.
FT   TURN        523    525       {ECO:0000244|PDB:1P0I}.
FT   STRAND      527    531       {ECO:0000244|PDB:1P0I}.
FT   STRAND      538    541       {ECO:0000244|PDB:1P0I}.
FT   HELIX       544    551       {ECO:0000244|PDB:1P0I}.
FT   TURN        552    555       {ECO:0000244|PDB:1P0I}.
SQ   SEQUENCE   602 AA;  68418 MW;  C9836409D9057F27 CRC64;
     MHSKVTIICI RFLFWFLLLC MLIGKSHTED DIIIATKNGK VRGMNLTVFG GTVTAFLGIP
     YAQPPLGRLR FKKPQSLTKW SDIWNATKYA NSCCQNIDQS FPGFHGSEMW NPNTDLSEDC
     LYLNVWIPAP KPKNATVLIW IYGGGFQTGT SSLHVYDGKF LARVERVIVV SMNYRVGALG
     FLALPGNPEA PGNMGLFDQQ LALQWVQKNI AAFGGNPKSV TLFGESAGAA SVSLHLLSPG
     SHSLFTRAIL QSGSFNAPWA VTSLYEARNR TLNLAKLTGC SRENETEIIK CLRNKDPQEI
     LLNEAFVVPY GTPLSVNFGP TVDGDFLTDM PDILLELGQF KKTQILVGVN KDEGTAFLVY
     GAPGFSKDNN SIITRKEFQE GLKIFFPGVS EFGKESILFH YTDWVDDQRP ENYREALGDV
     VGDYNFICPA LEFTKKFSEW GNNAFFYYFE HRSSKLPWPE WMGVMHGYEI EFVFGLPLER
     RDNYTKAEEI LSRSIVKRWA NFAKYGNPNE TQNNSTSWPV FKSTEQKYLT LNTESTRIMT
     KLRAQQCRFW TSFFPKVLEM TGNIDEAEWE WKAGFHRWNN YMMDWKNQFN DYTSKKESCV
     GL
//
